Advertisement
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line
(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.
Charles River Research Models & Services (RMS) sales and marketing teams will collaborate with DURECT to jointly market and commercialize the ALZET product line to existing and new customers over a multi-year period.
Charles River RMS will provide dedicated marketing resources and collaborate with DURECT to develop and roll out a broad range of sales and marketing initiatives for ALZET.
DURECT will remain responsible for manufacturing, marketing support, order fulfillment and customer billing.
read more
Charles River Laboratories Slashes FY24 Outlook - Update
While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews
|
453 วันที่ผ่านมา
Charles River Laboratories Reaffirms FY24 Outlook; Q1 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) reaffirmed its adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2024.
RTTNews
|
543 วันที่ผ่านมา
Charles River Laboratories Narrows FY23 Outlook Range; Q3 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) narrowed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance range for the full-year 2023.
RTTNews
|
726 วันที่ผ่านมา
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates
While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews
|
907 วันที่ผ่านมา
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss
While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews
|
1188 วันที่ผ่านมา
DURECT Appoints Timothy Papp As New CFO
Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews
|
1217 วันที่ผ่านมา
Bay Street Likely To Open On Positive Note
Canadian shares are likely to open higher Monday morning, with firm metal prices expected to trigger buying in the materials sector. The focus will be on the developments on the trade front and corporate earnings announcements.
RTTNews
|
2 ชม. 0 นาทีที่ผ่านมา
FedEx Study Reveals $126 Bln Contribution In Direct & Indirect Impact To Global Economy In FY25
FedEx Corp. has contributed $126 billion in direct and indirect impact to the global economy in fiscal 2025, according to the logistics major's annual Global Economic Impact Report. The company delivered $1.6 billion in direct and indirect impact in the Middle East, Indian Subcontinent, and Africa or MEISA region.
RTTNews
|
2 ชม. 21 นาทีที่ผ่านมา
